# China IUCD Market

> China IUCD Market Research Report Information, by type (Hormonal IUD, Copper IUD and others), by end users (Hospitals, Clinics and others) - Growth & Industry Forecast 2025 To 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 6.5%
- **2024:** $ 13.74 Billion
- **2025:** $ 14.63 Billion
- **2035:** $ 27.47 Billion
- **Key Players:** Bayer AG (DE), Merck & Co. Inc. (US), CooperSurgical Inc. (US), Hologic Inc. (US), Shanghai Dahua Medical Instrument Co. Ltd. (CN), Tianjin Ciming Pharmaceutical Co. Ltd. (CN), Qingdao Hainuo Medical Technology Co. Ltd. (CN), Sino-Pharma (CN)

**Report ID:** MRFR/MED/0798-HCR · **Pages:** 80 · **Author:** Nidhi Mandole & Rahul Gotadki · **Last Updated:** April 06, 2026

**URL:** https://www.marketresearchfuture.com/reports/china-iucd-market-1306

---

## Market Summary

## **China IUCD Market Overview**

China Iucd Market Size was valued at USD 13.05 Billion in 2023. The Global China Iucd industry is projected to grow from USD 13.74 Billion in 2024 to USD 24.31 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 10.45% during the forecast period (2024 - 2032). IUCD stands for Intra-Uterine Contraceptive Devices. It is a device inserted into the uterus to prevent pregnancy. The device is T-shaped made up of flexible plastic with a coating of thin copper wire. China, ICUD was the most important tool to limit the couples to have one child.

One child policy of China was introduced in 1979 favored the growth of this market till 2015. 

But in January 2016, a new law named “Two-child policy” become effective, which was passed by standing committee of National People’s Congress in December 2016. According to census 2010, the population change in is 7.39 per year. The market for IUCD is showing a steady rise in China because most of the women still do not want to have a second child even after the passage of second child policy. The increasing incidence of unplanned pregnancies, particularly among young females, and the rising need to control population growth are the key factors driving the intrauterine contraceptive devices market in China.

Similar to oral contraceptives, IUDs offer several benefits, including reduced side effects, which is a significant motivating factor. In addition, government initiatives that are favorable would further stimulate the market.

The market for intrauterine contraceptives is expanding due to the numerous positive characteristics of these products. Government programs that emphasize the advantages of IUD use have a substantial effect on market demand. Even in developing nations, disseminating the word about these instruments is motivated solely by their necessity. The market for intrauterine contraceptive devices is expanding rapidly due to rising demand and the stimulating effect of continuous innovation.

Market expansion is anticipated to be driven by an increase in demand from women who want to voluntarily delay having children. It is anticipated that the implementation of innovative strategies by the United States government to increase access to sexual and reproductive health services and products will increase the number of individuals interested in delaying pregnancy. Government and non-government organizations have made significant advances in recent years to expand access to intrauterine contraceptive devices in an effort to reduce the number of abortions and unintended pregnancies.

To prevent unwanted pregnancies and hazardous abortions, more women must have access to and utilize contraceptives such as intrauterine devices. In addition to the high product adoption rates for preventing unintended pregnancies, it has significant implications. In the future years, the far-reaching effects of unintended pregnancies are anticipated to increase market opportunities for IUDs.

**May 2023:**In honor of Women's Health Month, Bayer is shining a national spotlight on the impact of the underdiscussed and underdiagnosed condition of heavy menstrual bleeding (HMB) and the fact that Mirena® (levonorgestrel-releasing intrauterine system) 52 mg is an FDA-approved IUD for the treatment of heavy periods for up to 5 years in women who choose an IUD for birth control. The company's innovations have shaped and defined the women's healthcare landscape, from the introduction of the first birth control pill in 1961 to Mirena, the most commonly prescribed IUD in the United States.

**Study objectives:**

** ****China IUCD Market****Key Players**

## **China IUCD Market Segmentation**

The China IUCD Market is segmented into types which include hormonal IUD, copper IUD and other types. The end users are hospitals, Clinics and others.

**In October 2022,** a new company plans to use a technology originally developed for use on horses to create a less painful intrauterine device. IUDs are one of the most effective birth control methods, but insertion and removal can be excruciating. 3Daughters desires to supplant T-shaped IUDs with its novel magnetic, frameless IUD. The venture raised slightly more than one million dollars to advance its mission.

Copper IUDs are the only FDA-approved, extremely effective, hormone-free, reversible contraception option for women in the United States, and their design has not changed significantly in the past 35 years, according to researchers from the University of California. The Sebela Pharmaceuticals-developed IUD under study is a low-dose model with several advantageous design features. During the first year of use, a copper IUD with a novel design was safe, effective, and well-tolerated by women, according to the findings of a phase 3 clinical trial.

## China IUCD Market Regional Analysis

On the basis of regions China IUCD Market is segmented into North China, Northeast China, East China, South Central China, Southwest China and Northwest China. East China account for the largest market share. It has the highest population and largest population density. The market in China is showing steady growth due to an increase in the population in all the regions. **Intended Audience**

The report for IUCD of Market Research Future comprises of extensive primary research along with the detailed analysis of qualitative as well as quantitative aspects by various industry experts, key opinion leaders to gain the deeper insight of the market and industry performance. The report gives the clear picture of current market scenario which includes historical and projected market size in terms of value and volume, technological advancement, macro economical and governing factors in the market. The report provides details information and strategies of the top key players in the industry.

The report also gives a broad study of the different markets segments and regions

## Market Drivers

### Rising Healthcare Expenditure

The China IUCD Market is poised for growth due to the rising healthcare expenditure in the country. As the government and private sectors increase their investments in healthcare, access to reproductive health services is improving. Recent data suggests that healthcare spending in China has seen a year-on-year increase of approximately 10%, which is expected to continue. This rise in expenditure is facilitating better access to IUCDs and related services, thereby encouraging more women to consider these options. Additionally, as healthcare facilities upgrade their services, the availability of IUCDs is likely to expand, further driving market growth. The correlation between increased healthcare spending and the accessibility of reproductive health services is a key driver for the China IUCD Market.

### Government Initiatives and Support

The China IUCD Market benefits significantly from various government initiatives aimed at promoting reproductive health. The government has implemented policies that encourage the use of contraceptives, including IUCDs, as part of its broader family planning strategy. Recent reports indicate that the government has allocated substantial funding to improve access to reproductive health services, particularly in rural areas. This support is crucial, as it not only raises awareness but also facilitates the distribution of IUCDs. Furthermore, educational campaigns are being launched to inform women about the benefits and safety of IUCDs, which is expected to bolster market growth. The proactive stance of the government in promoting reproductive health is likely to have a lasting impact on the China IUCD Market.

### Cultural Shifts Towards Family Planning

Cultural shifts in attitudes towards family planning are significantly influencing the China IUCD Market. Traditionally, family planning was often viewed through a conservative lens; however, there is a noticeable change in perceptions among younger generations. Increasingly, women are prioritizing their careers and personal aspirations, leading to a greater acceptance of contraceptive methods like IUCDs. Surveys indicate that over 40% of women aged 20-35 are now more open to discussing and utilizing IUCDs as a viable option for family planning. This cultural evolution is likely to encourage manufacturers to tailor their marketing strategies to resonate with this demographic, thereby enhancing the overall growth of the China IUCD Market.

### Innovations in IUCD Design and Functionality

Innovations in the design and functionality of IUCDs are emerging as a pivotal driver for the China IUCD Market. Manufacturers are increasingly focusing on developing IUCDs that are not only more effective but also more comfortable for users. Recent advancements include the introduction of smaller, more flexible IUCDs that reduce discomfort during insertion and use. Additionally, some new designs incorporate materials that minimize side effects, which could enhance user satisfaction. As these innovations gain traction, they are likely to attract a broader audience, including those who may have previously been hesitant to use IUCDs. The emphasis on research and development in the China IUCD Market is expected to yield products that better meet the needs of consumers.

### Increasing Demand for Long-Acting Contraceptives

The China IUCD Market is experiencing a notable increase in demand for long-acting contraceptive methods. This trend is largely driven by a growing awareness among women regarding family planning and reproductive health. According to recent statistics, approximately 30% of women in urban areas are opting for IUCDs as their preferred method of contraception. This shift is indicative of a broader societal change, where women are seeking reliable and effective means to manage their reproductive health. The convenience and effectiveness of IUCDs, which can last for several years, align well with the preferences of modern women. As a result, manufacturers in the China IUCD Market are likely to focus on enhancing product offerings to meet this rising demand.

## Future Outlook

The China IUCD Market is projected to grow at a 6.5% CAGR from 2025 to 2035, driven by increasing awareness, government initiatives, and advancements in technology.

**New opportunities:**

- Expansion of telehealth services for IUCD consultations
- Development of biodegradable IUCDs to meet sustainability demands
- Partnerships with healthcare providers for integrated IUCD distribution

By 2035, the market is expected to be robust, driven by innovation and strategic partnerships.

## Segment Insights

### By Type: Hormonal IUD (Largest) vs. Copper IUD (Fastest-Growing)

In the China IUCD Market, the distribution of market share among the different types of intrauterine contraceptive devices reveals a significant dominance of Hormonal IUDs. This segment has garnered substantial attention due to its dual benefits of contraception and therapeutic effects, leading to a strong foothold in the market. Meanwhile, the Copper IUD is showing rapid growth, appealing to those seeking non-hormonal options, which has been particularly relevant in recent years due to increasing awareness about hormonal side effects among consumers. 
The growth trends within this segment indicate that while Hormonal IUDs remain the preferred choice among a large portion of the population, there is a noticeable shift toward Copper IUDs. Factors such as changing attitudes towards contraception, the desire for longer-lasting solutions, and the emphasis on natural options are driving the demand for Copper IUDs. This dynamic in consumer preferences suggests a promising future for both types as they cater to varied needs in reproductive health.

Hormonal IUD (Dominant) vs. Copper IUD (Emerging)

The Hormonal IUD segment is characterized by its ability to provide both effective contraception and additional health benefits, such as regulation of menstrual cycles. This has contributed to its dominant market position in China. Additionally, the ease of use and low failure rates have solidified its popularity among women seeking reliable long-term solutions. On the other hand, the Copper IUD has emerged as a notable alternative, appealing to those who prefer non-hormonal contraceptive methods. Its rapid adoption is indicative of changing consumer awareness and preferences, particularly among younger women and those looking for longer-lasting options without hormonal intervention. With these distinguishing characteristics, both segments reflect the diversification in contraceptive methods available in the China IUCD Market.

### By End Users: Hospitals (Largest) vs. Clinics (Fastest-Growing)

In the China IUCD market, the end users are primarily categorized into hospitals, clinics, and other healthcare facilities. Among these, hospitals have established themselves as the largest segment, largely due to their comprehensive obstetric and gynecological services. This dominance is further accentuated by the availability of advanced medical technologies and skilled healthcare professionals, which enhance patient trust and contribute to better outcomes. Meanwhile, clinics represent the fastest-growing segment, attributed to their accessibility and the increasing preference of patients for outpatient services, leading to a rising demand for IUCDs amongst this user group.

Hospitals (Dominant) vs. Clinics (Emerging)

Hospitals play a dominant role in the China IUCD market as they are equipped with specialized services and resources that facilitate a wide range of reproductive health options. Patients often seek medical advice and procedures in hospitals due to the level of care provided, including post-insertion monitoring and follow-up services. On the other hand, clinics are viewed as emerging players in this landscape, gaining traction among patients who prefer more personalized and immediate healthcare services. The trend towards minimalistic, outpatient surgical procedures has enabled clinics to cater to a growing patient base, leading to a significant uptick in IUCD usage. As these segments evolve, the competition will intensify, pushing both to innovate and improve patient experiences.

## Regional Market Share Analysis

### North America : Market Stability and Growth

The North American IUCD market is characterized by stable demand driven by increasing awareness of contraceptive options and supportive healthcare policies. The U.S. holds the largest market share at approximately 70%, followed by Canada at around 20%. Regulatory support from organizations like the FDA has facilitated the introduction of innovative IUCDs, enhancing market growth. 

Leading players in this region include Merck & Co. Inc. and CooperSurgical Inc., which dominate the market with their advanced product offerings. The competitive landscape is marked by continuous innovation and strategic partnerships aimed at expanding product portfolios. The presence of established companies ensures a robust supply chain and distribution network, further solidifying market stability.

### Europe : Regulatory Support and Innovation

The European IUCD market is witnessing significant growth, driven by increasing healthcare investments and a rising focus on women's health. Germany and France are the largest markets, holding approximately 30% and 25% market shares, respectively. Regulatory frameworks from the European Medicines Agency (EMA) are pivotal in ensuring product safety and efficacy, fostering innovation in IUCD technologies. 

Countries like the UK and Italy are also contributing to market expansion, with a growing number of healthcare providers adopting IUCDs as a preferred contraceptive method. Key players such as Bayer AG and Hologic Inc. are actively involved in research and development, enhancing their competitive edge. The market is characterized by a mix of established brands and emerging companies, creating a dynamic landscape.

### Asia-Pacific : Rapid Growth and Adoption

The Asia-Pacific IUCD market is rapidly expanding, driven by increasing population awareness and government initiatives promoting family planning. China and India are the largest markets, accounting for approximately 40% and 30% of the regional share, respectively. Regulatory support from local health authorities is crucial in facilitating the adoption of IUCDs, contributing to a growing acceptance among women. 

China's market is particularly influenced by local manufacturers like Shanghai Dahua Medical Instrument Co. Ltd. and Tianjin Ciming Pharmaceutical Co. Ltd., which are enhancing product availability. The competitive landscape is evolving, with both domestic and international players vying for market share. The increasing focus on reproductive health is expected to further drive demand for IUCDs in the region.

### Middle East and Africa : Emerging Market Dynamics

The Middle East and Africa IUCD market is emerging, driven by increasing healthcare access and awareness of contraceptive options. Countries like South Africa and Nigeria are leading the market, holding approximately 35% and 25% shares, respectively. Government initiatives aimed at improving reproductive health services are acting as catalysts for market growth, encouraging the adoption of IUCDs. 

The competitive landscape is characterized by a mix of local and international players, with companies like Sino-Pharma making significant inroads. The presence of key players is essential for enhancing product distribution and availability. As healthcare infrastructure improves, the demand for IUCDs is expected to rise, presenting substantial growth opportunities in this region.

## Competitive Benchmarking

The China IUCD Market is characterized by a dynamic competitive landscape, driven by increasing demand for effective contraceptive solutions and a growing awareness of reproductive health. Key players such as Bayer AG (Germany), Merck & Co. Inc. (US), and Shanghai Dahua Medical Instrument Co. Ltd. (China) are strategically positioned to leverage innovation and regional expansion. Bayer AG (Germany) focuses on enhancing its product portfolio through research and development, while Merck & Co. Inc. (US) emphasizes partnerships with local healthcare providers to improve market penetration. Shanghai Dahua Medical Instrument Co. Ltd. (China) appears to be concentrating on local manufacturing capabilities to cater to the specific needs of the Chinese market, thereby shaping a competitive environment that is increasingly focused on tailored solutions.

The business tactics employed by these companies include localizing manufacturing and optimizing supply chains to enhance efficiency and reduce costs. The market structure is moderately fragmented, with several domestic and international players vying for market share. This fragmentation allows for a diverse range of products and services, but also intensifies competition among key players, who must continuously innovate to maintain their positions.

In August 2025, Bayer AG (Germany) announced a strategic partnership with a leading Chinese healthcare provider to enhance access to its IUCD products across rural areas. This move is significant as it not only expands Bayer's distribution network but also aligns with the Chinese government's initiatives to improve reproductive health services in underserved regions. Such partnerships may prove crucial in establishing a strong foothold in a market that values accessibility and localized solutions.

In September 2025, Merck & Co. Inc. (US) launched a new IUCD product specifically designed for the Asian market, incorporating feedback from local healthcare professionals. This product launch is indicative of Merck's commitment to innovation and responsiveness to regional needs, potentially positioning the company as a leader in the IUCD segment. By tailoring products to meet local demands, Merck may enhance its competitive edge in a rapidly evolving market.

In July 2025, Shanghai Dahua Medical Instrument Co. Ltd. (China) expanded its manufacturing capabilities by investing in advanced production technologies. This investment is likely to improve product quality and reduce lead times, thereby enhancing the company's ability to compete effectively against both domestic and international rivals. Such advancements in manufacturing could be pivotal in meeting the growing demand for IUCDs in China.

As of October 2025, current competitive trends in the China IUCD Market include a pronounced shift towards digitalization, sustainability, and the integration of artificial intelligence in product development and marketing strategies. Strategic alliances are increasingly shaping the landscape, allowing companies to pool resources and expertise. Looking ahead, competitive differentiation is expected to evolve from traditional price-based competition to a focus on innovation, technological advancements, and supply chain reliability, reflecting a broader trend towards value-driven offerings in the healthcare sector.

## Report Scope

| MARKET SIZE 2024 | 13.74(USD Billion) |
| --- | --- |
| MARKET SIZE 2025 | 14.63(USD Billion) |
| MARKET SIZE 2035 | 27.47(USD Billion) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 6.5% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Billion |
| Key Companies Profiled | Bayer AG (DE), Merck & Co. Inc. (US), CooperSurgical Inc. (US), Hologic Inc. (US), Shanghai Dahua Medical Instrument Co. Ltd. (CN), Tianjin Ciming Pharmaceutical Co. Ltd. (CN), Qingdao Hainuo Medical Technology Co. Ltd. (CN), Sino-Pharma (CN) |
| Segments Covered | type, end users |
| Key Market Opportunities | Growing demand for long-acting reversible contraception drives innovation in the China IUCD Market. |
| Key Market Dynamics | Rising demand for intrauterine contraceptive devices driven by changing consumer preferences and regulatory support in China. |
| Countries Covered | North America, Europe, APAC, South America, MEA |

## Frequently Asked Questions

**Q: What is the current valuation of the China IUCD Market as of 2024?**
A: The overall market valuation of the China IUCD Market was 13.74 USD Billion in 2024.

**Q: What is the projected market valuation for the China IUCD Market in 2035?**
A: The projected valuation for the China IUCD Market in 2035 is 27.47 USD Billion.

**Q: What is the expected CAGR for the China IUCD Market during the forecast period 2025 - 2035?**
A: The expected CAGR for the China IUCD Market during the forecast period 2025 - 2035 is 6.5%.

**Q: Which segments are included in the China IUCD Market analysis?**
A: The segments in the China IUCD Market include Type and End Users.

**Q: What were the valuations for Hormonal IUDs in 2024 and the projected value in 2035?**
A: The valuation for Hormonal IUDs was 4.13 USD Billion in 2024 and is projected to reach 8.27 USD Billion in 2035.

**Q: How did the Copper IUD segment perform in 2024 compared to its projection for 2035?**
A: The Copper IUD segment was valued at 6.18 USD Billion in 2024 and is expected to grow to 12.36 USD Billion by 2035.

**Q: What is the market size for the Other Types segment in the China IUCD Market?**
A: The Other Types segment was valued at 3.43 USD Billion in 2024 and is projected to reach 6.84 USD Billion in 2035.

**Q: Which end-user segments are analyzed in the China IUCD Market?**
A: The end-user segments analyzed include Hospitals, Clinics, and Others.

**Q: What were the valuations for Hospitals and Clinics in 2024?**
A: In 2024, the valuation for Hospitals was 5.51 USD Billion, while Clinics were valued at 4.12 USD Billion.

**Q: Who are the key players in the China IUCD Market?**
A: Key players in the China IUCD Market include Bayer AG, Merck & Co. Inc., CooperSurgical Inc., Hologic Inc., and several Chinese companies.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/china-iucd-market-1306*